{"id":51597,"date":"2022-12-06T10:02:32","date_gmt":"2022-12-06T09:02:32","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/congenica-awarded-second-stage-of-european-contract-to-develop-ngs-analysis-workflow-in-oncology\/"},"modified":"2022-12-06T10:02:32","modified_gmt":"2022-12-06T09:02:32","slug":"congenica-awarded-second-stage-of-european-contract-to-develop-ngs-analysis-workflow-in-oncology","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/congenica-awarded-second-stage-of-european-contract-to-develop-ngs-analysis-workflow-in-oncology\/","title":{"rendered":"Congenica awarded second stage of European contract to develop NGS analysis workflow in oncology"},"content":{"rendered":"<div>\n<p>CAMBRIDGE, England&#8211;(BUSINESS WIRE)&#8211;<a href=\"https:\/\/twitter.com\/hashtag\/lifechanginganswers?src=hash\" target=\"_blank\" rel=\"noopener\">#lifechanginganswers<\/a>&#8211;Congenica, a UK-based digital health company that enables the rapid analysis and interpretation of genomic data, has been awarded the second stage of a contract to develop standardised Next-Generation Sequencing (NGS) workflows in oncology for a group of seven Central European hospitals represented by the Medical University Graz.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20221206005151\/en\/1655381\/5\/Congenica_Logo_With_Tagline_RGB.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20221206005151\/en\/1655381\/21\/Congenica_Logo_With_Tagline_RGB.jpg\"><\/a><\/p>\n<p>\nThe European Union Horizon 2020 funded project, \u2018About INtegrated and STANDardized NGS workflows FOR Personalized therapy\u2019 (Instand-NGS4P), has been set up to support the development of integrated and standardised Next Generation Sequencing (NGS) workflows to guide therapy decisions and provide clinical decision support at bedside of cancer patients.\n<\/p>\n<p>\nAs technological advances combined with clinical needs increasingly drive the adoption of cancer genomics into routine cancer care, the provision of individualised therapeutic recommendations specific to the diagnosis and genomic profiles of these individuals is crucial. To accelerate these advances, Congenica is developing a fully automated and integrated data analysis and reporting platform that will enable evidence-based interpretation of NGS data with focus on actionable insights for rapid treatment decision support at bedside.\n<\/p>\n<p>\nAlastair Johnson, Chief Professional Services Officer at Congenica, said: \u201cWe are delighted to be part of this exciting project. Our oncology application will offer cancer patients across Europe the utmost benefit from NGS data and rapid access to personalised healthcare. With a commitment to global quality standards, our fully automated and end-to-end solution will help drive precision medicine and deliver high quality patient care to shape the future of human health.\u201d\n<\/p>\n<p>\nCongenica was selected for the second stage of this project in October 2022 from several highly competitive applications, which were assessed in a multi-step peer-reviewed process. Phase 2 will focus on the delivery of a product prototype and is scheduled for completion in March 2024.\n<\/p>\n<p>\nEnds\n<\/p>\n<p>\n<b>About Congenica<\/b>\n<\/p>\n<p>\nCongenica is a digital health company enabling the rapid analysis and interpretation of genomic data. Congenica empowers researchers and clinicians to provide life-changing answers that improve wellbeing and disease management. Congenica\u2019s world-leading software enables rapid genomic data analysis at scale and is the only product of its kind that has received the CE Mark under the In Vitro Diagnostics Directive.\n<\/p>\n<p>\nA recognised leader in the genomic analysis of rare diseases and inherited cancer, Congenica is now expanding its platform into somatic cancer with the goal of helping to deliver a future where clinical genomics is fully integrated into healthcare.\n<\/p>\n<p>\nBased on pioneering research from the Wellcome Sanger Institute and the UK NHS, Congenica has a global footprint supporting leading international laboratories, academic medical centres and biopharmaceutical companies and is the exclusive Clinical Decision Support partner for the NHS Genomic Medicine Service.\n<\/p>\n<p>\nFor more information visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.congenica.com&amp;esheet=53005138&amp;newsitemid=20221206005151&amp;lan=en-US&amp;anchor=www.congenica.com&amp;index=1&amp;md5=e7d46a683ec37719f648a72be11dc9bf\" rel=\"nofollow noopener\" shape=\"rect\">www.congenica.com<\/a>\n<\/p>\n<p>\n<b>About INtegrated and STANDardized NGS workflows FOR Personalized therapy (INSTAND-NGS4P, Grant No. 874719)<\/b>\n<\/p>\n<p>\nA Pre-Procurement Project for improving cancer patients\u2019 benefit from Next Generation Sequencing (NGS) by developing an integrated and standardized NGS workflow and integrating information from cancer gene testing, pharmacogenetics testing and e-medication in proper presentation to medical doctors for supporting therapy decision making at bedside. This 65-month H2020 project started in January 2020.\n<\/p>\n<p>\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.instandngs4p.eu%2F&amp;esheet=53005138&amp;newsitemid=20221206005151&amp;lan=en-US&amp;anchor=www.instandngs4p.eu%2F&amp;index=2&amp;md5=c3ea792bb331ed396ff3576f719007f8\" rel=\"nofollow noopener\" shape=\"rect\">www.instandngs4p.eu\/<\/a>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nBecky Lamont, Marketing Communications Manager at Congenica<br \/>\n<br \/>00 44 (0)7468 698315 <a target=\"_blank\" href=\"ma&#105;&#108;&#116;&#111;&#x3a;&#x62;&#x65;&#x63;&#x6b;y&#46;&#108;&#97;&#109;&#111;&#x6e;&#x74;&#x40;&#x63;&#x6f;ng&#101;&#110;&#105;&#99;&#x61;&#x2e;&#x63;&#x6f;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">b&#101;&#x63;&#x6b;y&#46;&#108;&#x61;&#x6d;o&#110;&#116;&#x40;&#x63;o&#110;&#x67;&#x65;&#x6e;i&#99;&#x61;&#x2e;c&#111;&#109;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, England&#8211;(BUSINESS WIRE)&#8211;#lifechanginganswers&#8211;Congenica, a UK-based digital health company that enables the rapid analysis and interpretation of genomic data, has been awarded the second stage of a contract to develop standardised Next-Generation Sequencing (NGS) workflows in oncology for a group of seven Central European hospitals represented by the Medical University Graz. The European Union Horizon 2020 &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/congenica-awarded-second-stage-of-european-contract-to-develop-ngs-analysis-workflow-in-oncology\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-51597","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Congenica awarded second stage of European contract to develop NGS analysis workflow in oncology - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/congenica-awarded-second-stage-of-european-contract-to-develop-ngs-analysis-workflow-in-oncology\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Congenica awarded second stage of European contract to develop NGS analysis workflow in oncology - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, England&#8211;(BUSINESS WIRE)&#8211;#lifechanginganswers&#8211;Congenica, a UK-based digital health company that enables the rapid analysis and interpretation of genomic data, has been awarded the second stage of a contract to develop standardised Next-Generation Sequencing (NGS) workflows in oncology for a group of seven Central European hospitals represented by the Medical University Graz. The European Union Horizon 2020 ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/congenica-awarded-second-stage-of-european-contract-to-develop-ngs-analysis-workflow-in-oncology\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-06T09:02:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221206005151\/en\/1655381\/21\/Congenica_Logo_With_Tagline_RGB.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/congenica-awarded-second-stage-of-european-contract-to-develop-ngs-analysis-workflow-in-oncology\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/congenica-awarded-second-stage-of-european-contract-to-develop-ngs-analysis-workflow-in-oncology\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Congenica awarded second stage of European contract to develop NGS analysis workflow in oncology\",\"datePublished\":\"2022-12-06T09:02:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/congenica-awarded-second-stage-of-european-contract-to-develop-ngs-analysis-workflow-in-oncology\\\/\"},\"wordCount\":534,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/congenica-awarded-second-stage-of-european-contract-to-develop-ngs-analysis-workflow-in-oncology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221206005151\\\/en\\\/1655381\\\/21\\\/Congenica_Logo_With_Tagline_RGB.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/congenica-awarded-second-stage-of-european-contract-to-develop-ngs-analysis-workflow-in-oncology\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/congenica-awarded-second-stage-of-european-contract-to-develop-ngs-analysis-workflow-in-oncology\\\/\",\"name\":\"Congenica awarded second stage of European contract to develop NGS analysis workflow in oncology - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/congenica-awarded-second-stage-of-european-contract-to-develop-ngs-analysis-workflow-in-oncology\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/congenica-awarded-second-stage-of-european-contract-to-develop-ngs-analysis-workflow-in-oncology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221206005151\\\/en\\\/1655381\\\/21\\\/Congenica_Logo_With_Tagline_RGB.jpg\",\"datePublished\":\"2022-12-06T09:02:32+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/congenica-awarded-second-stage-of-european-contract-to-develop-ngs-analysis-workflow-in-oncology\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/congenica-awarded-second-stage-of-european-contract-to-develop-ngs-analysis-workflow-in-oncology\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/congenica-awarded-second-stage-of-european-contract-to-develop-ngs-analysis-workflow-in-oncology\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221206005151\\\/en\\\/1655381\\\/21\\\/Congenica_Logo_With_Tagline_RGB.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221206005151\\\/en\\\/1655381\\\/21\\\/Congenica_Logo_With_Tagline_RGB.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/congenica-awarded-second-stage-of-european-contract-to-develop-ngs-analysis-workflow-in-oncology\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Congenica awarded second stage of European contract to develop NGS analysis workflow in oncology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Congenica awarded second stage of European contract to develop NGS analysis workflow in oncology - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/congenica-awarded-second-stage-of-european-contract-to-develop-ngs-analysis-workflow-in-oncology\/","og_locale":"en_US","og_type":"article","og_title":"Congenica awarded second stage of European contract to develop NGS analysis workflow in oncology - Pharma Trend","og_description":"CAMBRIDGE, England&#8211;(BUSINESS WIRE)&#8211;#lifechanginganswers&#8211;Congenica, a UK-based digital health company that enables the rapid analysis and interpretation of genomic data, has been awarded the second stage of a contract to develop standardised Next-Generation Sequencing (NGS) workflows in oncology for a group of seven Central European hospitals represented by the Medical University Graz. The European Union Horizon 2020 ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/congenica-awarded-second-stage-of-european-contract-to-develop-ngs-analysis-workflow-in-oncology\/","og_site_name":"Pharma Trend","article_published_time":"2022-12-06T09:02:32+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221206005151\/en\/1655381\/21\/Congenica_Logo_With_Tagline_RGB.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/congenica-awarded-second-stage-of-european-contract-to-develop-ngs-analysis-workflow-in-oncology\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/congenica-awarded-second-stage-of-european-contract-to-develop-ngs-analysis-workflow-in-oncology\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Congenica awarded second stage of European contract to develop NGS analysis workflow in oncology","datePublished":"2022-12-06T09:02:32+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/congenica-awarded-second-stage-of-european-contract-to-develop-ngs-analysis-workflow-in-oncology\/"},"wordCount":534,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/congenica-awarded-second-stage-of-european-contract-to-develop-ngs-analysis-workflow-in-oncology\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221206005151\/en\/1655381\/21\/Congenica_Logo_With_Tagline_RGB.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/congenica-awarded-second-stage-of-european-contract-to-develop-ngs-analysis-workflow-in-oncology\/","url":"https:\/\/pharma-trend.com\/en\/congenica-awarded-second-stage-of-european-contract-to-develop-ngs-analysis-workflow-in-oncology\/","name":"Congenica awarded second stage of European contract to develop NGS analysis workflow in oncology - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/congenica-awarded-second-stage-of-european-contract-to-develop-ngs-analysis-workflow-in-oncology\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/congenica-awarded-second-stage-of-european-contract-to-develop-ngs-analysis-workflow-in-oncology\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221206005151\/en\/1655381\/21\/Congenica_Logo_With_Tagline_RGB.jpg","datePublished":"2022-12-06T09:02:32+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/congenica-awarded-second-stage-of-european-contract-to-develop-ngs-analysis-workflow-in-oncology\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/congenica-awarded-second-stage-of-european-contract-to-develop-ngs-analysis-workflow-in-oncology\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/congenica-awarded-second-stage-of-european-contract-to-develop-ngs-analysis-workflow-in-oncology\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221206005151\/en\/1655381\/21\/Congenica_Logo_With_Tagline_RGB.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221206005151\/en\/1655381\/21\/Congenica_Logo_With_Tagline_RGB.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/congenica-awarded-second-stage-of-european-contract-to-develop-ngs-analysis-workflow-in-oncology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Congenica awarded second stage of European contract to develop NGS analysis workflow in oncology"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51597","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=51597"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51597\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=51597"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=51597"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=51597"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}